HEADER TRANSFERASE/TRANSFERASE INHIBITOR 23-JUL-12 4G9C TITLE HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE TITLE 2 INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: SERINE/THREONINE-PROTEIN KINASE B-RAF; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: KINASE DOMAIN (UNP RESIDUES 432-726); COMPND 5 SYNONYM: PROTO-ONCOGENE B-RAF, P94, V-RAF MURINE SARCOMA VIRAL COMPND 6 ONCOGENE HOMOLOG B1; COMPND 7 EC: 2.7.11.1; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BRAF, BRAF1, RAFB1; SOURCE 6 EXPRESSION_SYSTEM: TRICHOPLUSIA NI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7111; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: HIGH FIVE KEYWDS DFG-OUT, INHIBITOR, TYPE II, TRANSFERASE, KINASE, TRANSFERASE- KEYWDS 2 TRANSFERASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR W.C.VOEGTLI,H.L.STURGIS REVDAT 2 28-FEB-24 4G9C 1 REMARK SEQADV REVDAT 1 14-NOV-12 4G9C 0 JRNL AUTH S.WENGLOWSKY,D.MORENO,E.R.LAIRD,S.L.GLOOR,L.REN,T.RISOM, JRNL AUTH 2 J.RUDOLPH,H.L.STURGIS,W.C.VOEGTLI JRNL TITL PYRAZOLOPYRIDINE INHIBITORS OF B-RAF(V600E). PART 4: JRNL TITL 2 RATIONAL DESIGN AND KINASE SELECTIVITY PROFILE OF CELL JRNL TITL 3 POTENT TYPE II INHIBITORS. JRNL REF BIOORG.MED.CHEM.LETT. V. 22 6237 2012 JRNL REFN ISSN 0960-894X JRNL PMID 22954737 JRNL DOI 10.1016/J.BMCL.2012.08.007 REMARK 2 REMARK 2 RESOLUTION. 3.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.76 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 4777125.660 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 95.3 REMARK 3 NUMBER OF REFLECTIONS : 11851 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.262 REMARK 3 R VALUE (WORKING SET) : 0.260 REMARK 3 FREE R VALUE : 0.291 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 6.100 REMARK 3 FREE R VALUE TEST SET COUNT : 723 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.011 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.2740 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.2720 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.303 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 6.100 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 723 REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : 0.0110 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 11851 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 3.50 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 3.72 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 96.80 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1831 REMARK 3 BIN R VALUE (WORKING SET) : 0.2960 REMARK 3 BIN FREE R VALUE : 0.3360 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 6.00 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 117 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.031 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4215 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 72 REMARK 3 SOLVENT ATOMS : 0 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 155.5 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 52.20 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -9.14000 REMARK 3 B22 (A**2) : -9.14000 REMARK 3 B33 (A**2) : 18.29000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.40 REMARK 3 ESD FROM SIGMAA (A) : 0.50 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.47 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.52 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.007 REMARK 3 BOND ANGLES (DEGREES) : 0.900 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 22.60 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.600 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.700 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 3.150 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 1.500 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 2.660 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.31 REMARK 3 BSOL : 43.67 REMARK 3 REMARK 3 NCS MODEL : CONSTR REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARA REMARK 3 PARAMETER FILE 2 : AR00460174.PAR REMARK 3 PARAMETER FILE 3 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : AR00460174.TOP REMARK 3 TOPOLOGY FILE 3 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4G9C COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 27-JUL-12. REMARK 100 THE DEPOSITION ID IS D_1000073901. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 22-JUL-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 9.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRL REMARK 200 BEAMLINE : BL7-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.979 REMARK 200 MONOCHROMATOR : SYNCHROTRON SILICON CRYSTAL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 315 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 11862 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.500 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 96.5 REMARK 200 DATA REDUNDANCY : 3.100 REMARK 200 R MERGE (I) : 0.11100 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 6.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.69 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.4 REMARK 200 DATA REDUNDANCY IN SHELL : 3.20 REMARK 200 R MERGE FOR SHELL (I) : 0.36900 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 62.63 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.29 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 100 MM TRIS PH 9.0, PEG 8000, VAPOR REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 41 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -Y+1/2,X+1/2,Z+1/4 REMARK 290 4555 Y+1/2,-X+1/2,Z+3/4 REMARK 290 5555 -X+1/2,Y+1/2,-Z+1/4 REMARK 290 6555 X+1/2,-Y+1/2,-Z+3/4 REMARK 290 7555 Y,X,-Z REMARK 290 8555 -Y,-X,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 80.92500 REMARK 290 SMTRY1 3 0.000000 -1.000000 0.000000 53.52500 REMARK 290 SMTRY2 3 1.000000 0.000000 0.000000 53.52500 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 40.46250 REMARK 290 SMTRY1 4 0.000000 1.000000 0.000000 53.52500 REMARK 290 SMTRY2 4 -1.000000 0.000000 0.000000 53.52500 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 121.38750 REMARK 290 SMTRY1 5 -1.000000 0.000000 0.000000 53.52500 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 53.52500 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 40.46250 REMARK 290 SMTRY1 6 1.000000 0.000000 0.000000 53.52500 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 53.52500 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 121.38750 REMARK 290 SMTRY1 7 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY2 7 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 80.92500 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: PROTEIN EXISTS IN AN EQUILIBRIUM BETWEEN MONOMER AND DIMER REMARK 300 STATE IN SOLUTION REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 420 REMARK 465 ASP A 421 REMARK 465 ARG A 422 REMARK 465 GLY A 423 REMARK 465 SER A 424 REMARK 465 HIS A 425 REMARK 465 HIS A 426 REMARK 465 HIS A 427 REMARK 465 HIS A 428 REMARK 465 HIS A 429 REMARK 465 HIS A 430 REMARK 465 GLY A 431 REMARK 465 SER A 432 REMARK 465 GLU A 433 REMARK 465 ASP A 434 REMARK 465 ARG A 435 REMARK 465 ASN A 436 REMARK 465 ARG A 437 REMARK 465 MET A 438 REMARK 465 LYS A 439 REMARK 465 THR A 440 REMARK 465 LEU A 441 REMARK 465 GLY A 442 REMARK 465 ARG A 443 REMARK 465 ARG A 444 REMARK 465 ASP A 445 REMARK 465 SER A 446 REMARK 465 SER A 447 REMARK 465 SER A 602 REMARK 465 ARG A 603 REMARK 465 TRP A 604 REMARK 465 SER A 605 REMARK 465 GLY A 606 REMARK 465 SER A 607 REMARK 465 HIS A 608 REMARK 465 GLN A 609 REMARK 465 PHE A 610 REMARK 465 GLU A 611 REMARK 465 GLN A 612 REMARK 465 ILE A 724 REMARK 465 HIS A 725 REMARK 465 ARG A 726 REMARK 465 MET B 420 REMARK 465 ASP B 421 REMARK 465 ARG B 422 REMARK 465 GLY B 423 REMARK 465 SER B 424 REMARK 465 HIS B 425 REMARK 465 HIS B 426 REMARK 465 HIS B 427 REMARK 465 HIS B 428 REMARK 465 HIS B 429 REMARK 465 HIS B 430 REMARK 465 GLY B 431 REMARK 465 SER B 432 REMARK 465 GLU B 433 REMARK 465 ASP B 434 REMARK 465 ARG B 435 REMARK 465 ASN B 436 REMARK 465 ARG B 437 REMARK 465 MET B 438 REMARK 465 LYS B 439 REMARK 465 THR B 440 REMARK 465 LEU B 441 REMARK 465 GLY B 442 REMARK 465 ARG B 443 REMARK 465 ARG B 444 REMARK 465 ASP B 445 REMARK 465 SER B 446 REMARK 465 SER B 447 REMARK 465 LYS B 601 REMARK 465 SER B 602 REMARK 465 ARG B 603 REMARK 465 TRP B 604 REMARK 465 SER B 605 REMARK 465 GLY B 606 REMARK 465 SER B 607 REMARK 465 HIS B 608 REMARK 465 GLN B 609 REMARK 465 PHE B 610 REMARK 465 GLU B 611 REMARK 465 GLN B 612 REMARK 465 ILE B 724 REMARK 465 HIS B 725 REMARK 465 ARG B 726 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 522 CG CD CE NZ REMARK 470 LYS B 522 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TRP A 476 92.97 -164.45 REMARK 500 ARG A 509 93.10 -166.32 REMARK 500 LYS A 522 167.19 -43.07 REMARK 500 PRO A 523 97.48 -21.35 REMARK 500 GLN A 524 -26.57 114.35 REMARK 500 LEU A 525 118.07 83.05 REMARK 500 GLN A 530 154.67 -48.28 REMARK 500 ILE A 543 -67.21 -103.96 REMARK 500 ASP A 576 31.92 -162.46 REMARK 500 ASP A 587 -14.84 78.31 REMARK 500 THR A 589 79.82 59.79 REMARK 500 ASP A 594 68.22 -114.62 REMARK 500 THR A 599 66.08 89.35 REMARK 500 VAL A 600 -92.17 77.81 REMARK 500 SER A 614 -116.68 -63.56 REMARK 500 MET A 627 60.79 71.75 REMARK 500 GLN A 628 -91.55 -62.40 REMARK 500 ASP A 629 43.71 -100.70 REMARK 500 LYS A 630 -38.02 68.04 REMARK 500 LEU A 721 10.06 -170.81 REMARK 500 PRO A 722 -9.99 -56.15 REMARK 500 ILE B 463 -68.85 -95.38 REMARK 500 TRP B 476 91.56 -165.70 REMARK 500 ARG B 509 92.87 -166.42 REMARK 500 LYS B 522 167.04 -44.17 REMARK 500 PRO B 523 97.60 -21.47 REMARK 500 GLN B 524 -27.09 113.37 REMARK 500 LEU B 525 117.34 83.30 REMARK 500 GLN B 530 154.13 -47.37 REMARK 500 ILE B 543 -67.80 -103.75 REMARK 500 ARG B 575 -0.43 78.89 REMARK 500 ASP B 576 31.05 -162.01 REMARK 500 ASP B 587 -15.10 76.67 REMARK 500 THR B 589 79.33 59.46 REMARK 500 ASP B 594 70.68 -114.09 REMARK 500 LEU B 597 -87.03 -102.49 REMARK 500 THR B 599 151.53 73.00 REMARK 500 SER B 614 -116.41 -65.14 REMARK 500 MET B 627 61.09 71.50 REMARK 500 GLN B 628 -90.33 -62.51 REMARK 500 ASP B 629 44.09 -101.52 REMARK 500 LYS B 630 -37.80 67.41 REMARK 500 LEU B 721 10.02 -171.46 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 LEU B 597 ALA B 598 101.50 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 0WP A 801 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 0WP B 801 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4G9R RELATED DB: PDB DBREF 4G9C A 432 726 UNP P15056 BRAF_HUMAN 432 726 DBREF 4G9C B 432 726 UNP P15056 BRAF_HUMAN 432 726 SEQADV 4G9C MET A 420 UNP P15056 EXPRESSION TAG SEQADV 4G9C ASP A 421 UNP P15056 EXPRESSION TAG SEQADV 4G9C ARG A 422 UNP P15056 EXPRESSION TAG SEQADV 4G9C GLY A 423 UNP P15056 EXPRESSION TAG SEQADV 4G9C SER A 424 UNP P15056 EXPRESSION TAG SEQADV 4G9C HIS A 425 UNP P15056 EXPRESSION TAG SEQADV 4G9C HIS A 426 UNP P15056 EXPRESSION TAG SEQADV 4G9C HIS A 427 UNP P15056 EXPRESSION TAG SEQADV 4G9C HIS A 428 UNP P15056 EXPRESSION TAG SEQADV 4G9C HIS A 429 UNP P15056 EXPRESSION TAG SEQADV 4G9C HIS A 430 UNP P15056 EXPRESSION TAG SEQADV 4G9C GLY A 431 UNP P15056 EXPRESSION TAG SEQADV 4G9C MET B 420 UNP P15056 EXPRESSION TAG SEQADV 4G9C ASP B 421 UNP P15056 EXPRESSION TAG SEQADV 4G9C ARG B 422 UNP P15056 EXPRESSION TAG SEQADV 4G9C GLY B 423 UNP P15056 EXPRESSION TAG SEQADV 4G9C SER B 424 UNP P15056 EXPRESSION TAG SEQADV 4G9C HIS B 425 UNP P15056 EXPRESSION TAG SEQADV 4G9C HIS B 426 UNP P15056 EXPRESSION TAG SEQADV 4G9C HIS B 427 UNP P15056 EXPRESSION TAG SEQADV 4G9C HIS B 428 UNP P15056 EXPRESSION TAG SEQADV 4G9C HIS B 429 UNP P15056 EXPRESSION TAG SEQADV 4G9C HIS B 430 UNP P15056 EXPRESSION TAG SEQADV 4G9C GLY B 431 UNP P15056 EXPRESSION TAG SEQRES 1 A 307 MET ASP ARG GLY SER HIS HIS HIS HIS HIS HIS GLY SER SEQRES 2 A 307 GLU ASP ARG ASN ARG MET LYS THR LEU GLY ARG ARG ASP SEQRES 3 A 307 SER SER ASP ASP TRP GLU ILE PRO ASP GLY GLN ILE THR SEQRES 4 A 307 VAL GLY GLN ARG ILE GLY SER GLY SER PHE GLY THR VAL SEQRES 5 A 307 TYR LYS GLY LYS TRP HIS GLY ASP VAL ALA VAL LYS MET SEQRES 6 A 307 LEU ASN VAL THR ALA PRO THR PRO GLN GLN LEU GLN ALA SEQRES 7 A 307 PHE LYS ASN GLU VAL GLY VAL LEU ARG LYS THR ARG HIS SEQRES 8 A 307 VAL ASN ILE LEU LEU PHE MET GLY TYR SER THR LYS PRO SEQRES 9 A 307 GLN LEU ALA ILE VAL THR GLN TRP CYS GLU GLY SER SER SEQRES 10 A 307 LEU TYR HIS HIS LEU HIS ILE ILE GLU THR LYS PHE GLU SEQRES 11 A 307 MET ILE LYS LEU ILE ASP ILE ALA ARG GLN THR ALA GLN SEQRES 12 A 307 GLY MET ASP TYR LEU HIS ALA LYS SER ILE ILE HIS ARG SEQRES 13 A 307 ASP LEU LYS SER ASN ASN ILE PHE LEU HIS GLU ASP LEU SEQRES 14 A 307 THR VAL LYS ILE GLY ASP PHE GLY LEU ALA THR VAL LYS SEQRES 15 A 307 SER ARG TRP SER GLY SER HIS GLN PHE GLU GLN LEU SER SEQRES 16 A 307 GLY SER ILE LEU TRP MET ALA PRO GLU VAL ILE ARG MET SEQRES 17 A 307 GLN ASP LYS ASN PRO TYR SER PHE GLN SER ASP VAL TYR SEQRES 18 A 307 ALA PHE GLY ILE VAL LEU TYR GLU LEU MET THR GLY GLN SEQRES 19 A 307 LEU PRO TYR SER ASN ILE ASN ASN ARG ASP GLN ILE ILE SEQRES 20 A 307 PHE MET VAL GLY ARG GLY TYR LEU SER PRO ASP LEU SER SEQRES 21 A 307 LYS VAL ARG SER ASN CYS PRO LYS ALA MET LYS ARG LEU SEQRES 22 A 307 MET ALA GLU CYS LEU LYS LYS LYS ARG ASP GLU ARG PRO SEQRES 23 A 307 LEU PHE PRO GLN ILE LEU ALA SER ILE GLU LEU LEU ALA SEQRES 24 A 307 ARG SER LEU PRO LYS ILE HIS ARG SEQRES 1 B 307 MET ASP ARG GLY SER HIS HIS HIS HIS HIS HIS GLY SER SEQRES 2 B 307 GLU ASP ARG ASN ARG MET LYS THR LEU GLY ARG ARG ASP SEQRES 3 B 307 SER SER ASP ASP TRP GLU ILE PRO ASP GLY GLN ILE THR SEQRES 4 B 307 VAL GLY GLN ARG ILE GLY SER GLY SER PHE GLY THR VAL SEQRES 5 B 307 TYR LYS GLY LYS TRP HIS GLY ASP VAL ALA VAL LYS MET SEQRES 6 B 307 LEU ASN VAL THR ALA PRO THR PRO GLN GLN LEU GLN ALA SEQRES 7 B 307 PHE LYS ASN GLU VAL GLY VAL LEU ARG LYS THR ARG HIS SEQRES 8 B 307 VAL ASN ILE LEU LEU PHE MET GLY TYR SER THR LYS PRO SEQRES 9 B 307 GLN LEU ALA ILE VAL THR GLN TRP CYS GLU GLY SER SER SEQRES 10 B 307 LEU TYR HIS HIS LEU HIS ILE ILE GLU THR LYS PHE GLU SEQRES 11 B 307 MET ILE LYS LEU ILE ASP ILE ALA ARG GLN THR ALA GLN SEQRES 12 B 307 GLY MET ASP TYR LEU HIS ALA LYS SER ILE ILE HIS ARG SEQRES 13 B 307 ASP LEU LYS SER ASN ASN ILE PHE LEU HIS GLU ASP LEU SEQRES 14 B 307 THR VAL LYS ILE GLY ASP PHE GLY LEU ALA THR VAL LYS SEQRES 15 B 307 SER ARG TRP SER GLY SER HIS GLN PHE GLU GLN LEU SER SEQRES 16 B 307 GLY SER ILE LEU TRP MET ALA PRO GLU VAL ILE ARG MET SEQRES 17 B 307 GLN ASP LYS ASN PRO TYR SER PHE GLN SER ASP VAL TYR SEQRES 18 B 307 ALA PHE GLY ILE VAL LEU TYR GLU LEU MET THR GLY GLN SEQRES 19 B 307 LEU PRO TYR SER ASN ILE ASN ASN ARG ASP GLN ILE ILE SEQRES 20 B 307 PHE MET VAL GLY ARG GLY TYR LEU SER PRO ASP LEU SER SEQRES 21 B 307 LYS VAL ARG SER ASN CYS PRO LYS ALA MET LYS ARG LEU SEQRES 22 B 307 MET ALA GLU CYS LEU LYS LYS LYS ARG ASP GLU ARG PRO SEQRES 23 B 307 LEU PHE PRO GLN ILE LEU ALA SER ILE GLU LEU LEU ALA SEQRES 24 B 307 ARG SER LEU PRO LYS ILE HIS ARG HET 0WP A 801 36 HET 0WP B 801 36 HETNAM 0WP 3-{[3-(2-CYANOPROPAN-2-YL)BENZOYL]AMINO}-2,6-DIFLUORO- HETNAM 2 0WP N-(3-METHOXY-2H-PYRAZOLO[3,4-B]PYRIDIN-5-YL)BENZAMIDE FORMUL 3 0WP 2(C25 H20 F2 N6 O3) HELIX 1 1 THR A 491 ARG A 506 1 16 HELIX 2 2 LEU A 537 ILE A 543 1 7 HELIX 3 3 GLU A 549 LYS A 570 1 22 HELIX 4 4 ALA A 621 MET A 627 1 7 HELIX 5 5 SER A 634 GLY A 652 1 19 HELIX 6 6 ASN A 661 GLY A 672 1 12 HELIX 7 7 ASP A 677 VAL A 681 5 5 HELIX 8 8 PRO A 686 LEU A 697 1 12 HELIX 9 9 LYS A 700 ARG A 704 5 5 HELIX 10 10 LEU A 706 ALA A 718 1 13 HELIX 11 11 THR B 491 ARG B 506 1 16 HELIX 12 12 LEU B 537 ILE B 543 1 7 HELIX 13 13 GLU B 549 LYS B 570 1 22 HELIX 14 14 ALA B 621 MET B 627 1 7 HELIX 15 15 SER B 634 GLY B 652 1 19 HELIX 16 16 ASN B 661 GLY B 672 1 12 HELIX 17 17 ASP B 677 VAL B 681 5 5 HELIX 18 18 PRO B 686 LEU B 697 1 12 HELIX 19 19 LYS B 700 ARG B 704 5 5 HELIX 20 20 LEU B 706 ALA B 718 1 13 SHEET 1 A 5 THR A 458 GLY A 464 0 SHEET 2 A 5 VAL A 471 LYS A 475 -1 O VAL A 471 N GLY A 464 SHEET 3 A 5 ASP A 479 MET A 484 -1 O VAL A 482 N TYR A 472 SHEET 4 A 5 ALA A 526 GLN A 530 -1 O THR A 529 N ALA A 481 SHEET 5 A 5 PHE A 516 SER A 520 -1 N MET A 517 O VAL A 528 SHEET 1 B 3 GLY A 534 SER A 536 0 SHEET 2 B 3 ILE A 582 HIS A 585 -1 O LEU A 584 N SER A 535 SHEET 3 B 3 VAL A 590 ILE A 592 -1 O LYS A 591 N PHE A 583 SHEET 1 C 5 THR B 458 GLY B 464 0 SHEET 2 C 5 THR B 470 LYS B 475 -1 O VAL B 471 N GLY B 464 SHEET 3 C 5 ASP B 479 MET B 484 -1 O VAL B 482 N TYR B 472 SHEET 4 C 5 ALA B 526 GLN B 530 -1 O THR B 529 N ALA B 481 SHEET 5 C 5 PHE B 516 SER B 520 -1 N MET B 517 O VAL B 528 SHEET 1 D 3 GLY B 534 SER B 536 0 SHEET 2 D 3 ILE B 582 HIS B 585 -1 O LEU B 584 N SER B 535 SHEET 3 D 3 VAL B 590 ILE B 592 -1 O LYS B 591 N PHE B 583 SITE 1 AC1 18 ILE A 463 ALA A 481 LYS A 483 GLU A 501 SITE 2 AC1 18 VAL A 504 LEU A 505 ILE A 513 LEU A 514 SITE 3 AC1 18 ILE A 527 THR A 529 GLN A 530 TRP A 531 SITE 4 AC1 18 CYS A 532 ILE A 572 HIS A 574 PHE A 583 SITE 5 AC1 18 ASP A 594 PHE A 595 SITE 1 AC2 17 ILE B 463 ALA B 481 LYS B 483 GLU B 501 SITE 2 AC2 17 LEU B 505 LEU B 514 ILE B 527 THR B 529 SITE 3 AC2 17 GLN B 530 TRP B 531 CYS B 532 ILE B 573 SITE 4 AC2 17 HIS B 574 PHE B 583 GLY B 593 ASP B 594 SITE 5 AC2 17 PHE B 595 CRYST1 107.050 107.050 161.850 90.00 90.00 90.00 P 41 21 2 16 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.009341 0.000000 0.000000 0.00000 SCALE2 0.000000 0.009341 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006179 0.00000